### 9th March 2016

### TMT

Soitec	
Price EUR0.63	

Bloomberg	Bloomberg			SOI FP	
Reuters				SOIT.PA	
12-month High		R)	0	.9 / 0.5	
Market Cap (EU			146 304 1,293		
Ev (BG Estimate					
	Avg. 6m daily volume (000)				
3y EPS CAGR	3y EPS CAGR				
	6 M 31/12/15				
Absolute perf.	26.0%	-8.7%	12.5%	-1.6%	
Semiconductors	10.6%	-8.2%	-1.7%	-5.2%	
DJ Stoxx 600	7.4%	-7.7%	-6.0%	-7.7%	
YEnd Mar. (EURm)	<b>03/</b> 15	03/16e	03/17e	03/18e	
Sales	222.9	236.0	248.4	265.2	
% change		5.9%	5.3%	6.7%	
EBITDA	-67.9	40.5	38.1	41.9	
EBIT	-125.9	8.1	10.6	13.1	
% change		NS	29.9%	24.2%	
Net income	-107.8	-23.2	4.1	6.3	
% change		78.5%	NS	52.2%	
	<b>03/</b> 15	03/16e	<b>03/</b> 17e	<b>03/</b> 18e	
Operating margin	NM	3.4	4.3	5.0	
Net margin	NM	NM	1.4	2.4	
ROE	-516.1	2,691	5.2	7.3	
ROCE	-63.0	5.3	7.0	9.0	
Gearing	300.4	NM	NM	73.5	
(EUR)	<b>03/</b> 15	03/16e	<b>03/17</b> e	03/18e	
EPS	-0.51	-0.10	0.01	0.02	
% change	-	81.1%	NS	24.3%	
P/E	NS	NS	46.3x	37.3x	
FCF yield (%)	NM	NM	5.6%	4.4%	
Dividends (EUR)	0.00	0.00	0.00	0.00	
Div yield (%)	NM	NM	NM	NM	
EV/Sales	1.3x	1.3x	0.9x	0.8x	
EV/EBITDA	NS	7.5x	5.7x	5.0x	
EV/EBIT	NS	37.4x	20.5x	15.9x	



We adopt a more cautious scenario.

Fair Value EUR0.5 vs. EUR0.65 (-21%)

NEUTRAL

Soitec has published an update of its 2014-2015 annual report in which it shares 2017 guidance for sales and EBITDA margin for the first time. This cautious guidance prompts us to adopt a more cautious scenario with 1/ FY16 top line growth unchanged at 6%, 2/ FY17/FY18 top line growth lowered to 5-7% vs. 15-10% previously and 3/ FY17 EBITDA margin similar to FY16 at 15% (vs. 20% previously). As a result, we have cut our FV from EUR0.65 to EUR0.50.

### ANALYSIS

- Soitec has published an update of its 2014-2015 annual report in which the group shares FY17 guidance for sales and EBITDA margin for the first time. In this updated report, the group says that it expects growth in RF and Power products (200mm wafers) to offset the decline in PD-SOI sales. The group adds that it expects 2016 sales of slightly above EUR230m, in line with the Q4 guidance shared during the Q3 publication (Q4 up 10% seq.), and EBITDA margin of 15% for FY16 and FY17 in the Electronic division.
- As a result, we are adopting a more cautious scenario with a 5-7% growth for FY17/FY18. The group's caution in FY17/FY18 sales guidance leads us to lower our estimates. We adopt a softer scenario with 1/ FY16 top line growth unchanged at 6%, 2/ FY17/FY18 top line growth lowered to 5-7% vs. 15-10% previously. In addition, we also adopt a FY17 current operating profit margin of 7.5% in Electronic, which is similar to our FY16 expectation. Overall, we now expect current operating margin of 3.4%/4.3%/5.0% for FY16/FY17/FY18 respectively vs. 2.7%/4.3%/7.5% previously (EBITDA margin of 14.9%/15.3%/15.8%). We estimate the gross cash position at the end of 2016 at close to EUR41m.
- Note that Soitec announced in February that it is preparing two successive capital increases. The group announced that it intends to carry out two capital increases for a total amount in the range of EUR130m to EUR180m. First, a reserved capital increase of EUR76.5m for BPI France, CEA and a Chinese investment fund National Silicon Industry Group. The reserved capital increase is set to go ahead at a price of EUR0.55 per share (vs. the current share price of EUR0.50), triggering the issuance of about 139m shares, representing 55% of the current number of outstanding shares. In addition to that, the group is preparing a second capital increase with preferential subscription rights for a total amount to be determined in the range of EUR53.5m to EUR103.5m. The proposed amount will depend on potential 2018 OCEANE buy-back opportunities. Proceeds from the operations will be used to pay down debt and accelerate investments to develop Soitec's FD-SOI production capacities. Shareholders will vote on the capital increase on 11th April.

### VALUATION

- Note that given the advanced talks with quoted investors CEAI, BPI France and the Chinese
  investment fund National Silicon Industry Group, we have included all the impacts of the reserved
  capital increase in our FV. However, the second capital increase remains uncertain so far, as a
  result, we do not include any impact from this one. All other factors remaining equal, including the
  impact of the second capital increase (lower financial costs and higher production capacities / at
  current share price and for an amount of EUR103.5m) our FV would be EUR0.4.
- Soitec shares are trading on FY17e EV/Sales of 0.9x and FY17e EV/EBIT of 20.5x.

### **NEXT CATALYSTS**

- 11th April: Shareholders to vote on capital increase
- During April: Q4 2016e sales.

### Click here to download



Analyst : Dorian Terral 33(0) 1.56.68.75.92 dterral@bryangarnier.com Sector Team : Richard-Maxime Beaudoux Thomas Coudry Gregory Ramirez

## BRYAN, GARNIER & CO

## Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

DIN/	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a		
BUY	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of		
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock		
	will feature an introduction outlining the key reasons behind the opinion.		

NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

#### Distribution of stock ratings

BUY ratings 64.4%

NEUTRAL ratings 28.1%

SELL ratings 7.4%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer		
2	Issuer shareholding in Bryan Garnier	reholding in Bryan The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	er or liquidity A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	managerIn the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement       A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with th Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.		No
7	Research agreement       A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.		No
8	Analyst receipt or purchase of shares in IssuerThe investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.		No
9	Remuneration of analyst	tion of analyst The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	
10	Corporate finance client In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.		No
11	Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.		No
12	Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.		No
13	Bryan Garnier executive is an officer       A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.		No
14	Analyst disclosure The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.		Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

## BRYAN, GARNIER & CO

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudential et de		FINMA	
(FCA)	resolution (ACPR)			

### Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever. Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

### BRYAN, GARNIER & CO